Vitaros
Commercial- Indications
- Erectile dysfunction
Company intelligence / Profile preview
Apricus Biosciences developed innovative medicines primarily targeting sexual health and urology using its proprietary NexACT® drug delivery platform. Its lead product, Vitaros®, a topical treatment for erectile dysfunction, achieved approval and commercialization in Europe and Canada but failed to secure FDA approval. The company also advanced several other candidates including Fispemifene for male hypogonadism/lower urinary tract symptoms and Femprox for female sexual arousal disorder. In January 2019, Apricus merged with Seelos Therapeutics after years of financial challenges.
3 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Apricus Biosciences, Inc..